---
document_datetime: 2025-04-15 12:44:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/flucelvax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: flucelvax-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.1778473
conversion_datetime: 2025-12-27 09:20:57.478259
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Flucelvax

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------|
| II/0001              | Extension of indication to include treatment of children from 6 months of age and older for FLUCELVAX, based on results from study V130_14. This is a Phase III, Randomised, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based | 27/03/2025                          | 10/04/2025                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion for Flucelvax Procedure No. EMEA/H/C/006532/II/0001 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has been approved. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to implement changes to sections 4.4 and 4.5 of the SmPC to align them with the QRD guideline and reflect experience on co- administration with other vaccines. The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|